por John R. Fischer
, Senior Reporter | June 26, 2019
Medical imaging OEM and service provider MiE spent the weekend in sunny California discussing the benefits of its future cardiac PET system, Ancoris, at the SNMMI 2019 Annual Meeting.
The aim behind the stand-alone PET system is to bring simultaneous 3D cardiac PET perfusion and CFR to the U.S. market and provide a cost-efficient alternative to PET/CT scans performed for cardiac imaging.
“PET/CT is necessary for oncology, but not for cardiac,” Thomas Kühl, president of MiE — Gamma Camera and PET systems, told HCB News. “Our system is under a million dollars, but new PET/CTs are far above that. In addition, the service contract is more affordable for one modality.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
In addition to a more cost-effective service contract, much of the reduction in cost comes from the fewer room and power requirements associated with PET, compared to PET/CT.
While conventional stand-alone PET systems have a patient table limit of 350 pounds or less, Ancoris is intended to exceed that.
It also has a higher count rate capability for dose management and can be used for other types of studies, such as those of the brain.
“Perfusion fulfills the need for enhancement,” said Kühl. “The image quality is not as good all around the states as it should be. We are working to enhance image quality."
Ancoris is not yet FDA cleared. MiE hopes to receive the 510(k) submission by the end of this year and launch the product in 2020.